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Objective: The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions into distinct protein complexes (mTORC1 and
mTORC2) that regulates growth and metabolism. DEP-domain containing mTOR-interacting protein (DEPTOR) is part of these complexes and is
known to reduce their activity. Whether DEPTOR loss affects metabolism and organismal growth in vivo has never been tested.
Methods: We have generated a conditional transgenic mouse allowing the tissue-speciﬁc deletion of DEPTOR. This model was crossed with
CMV-cre mice or Albumin-cre mice to generate either whole-body or liver-speciﬁc DEPTOR knockout (KO) mice.
Results: Whole-body DEPTOR KO mice are viable, fertile, normal in size, and do not display any gross physical and metabolic abnormalities. To
circumvent possible compensatory mechanisms linked to the early and systemic loss of DEPTOR, we have deleted DEPTOR speciﬁcally in the
liver, a tissue in which DEPTOR protein is expressed and affected in response to mTOR activation. Liver-speciﬁc DEPTOR null mice showed a
reduction in circulating glucose upon fasting versus control mice. This effect was not associated with change in hepatic gluconeogenesis potential
but was linked to a sustained reduction in circulating glucose during insulin tolerance tests. In addition to the reduction in glycemia, liver-speciﬁc
DEPTOR KO mice had reduced hepatic glycogen content when fasted. We showed that loss of DEPTOR cell-autonomously increased oxidative
metabolism in hepatocytes, an effect associated with increased cytochrome c expression but independent of changes in mitochondrial content or
in the expression of genes controlling oxidative metabolism. We found that liver-speciﬁc DEPTOR KO mice showed sustained mTORC1 activation
upon fasting, and that acute treatment with rapamycin was sufﬁcient to normalize glycemia in these mice.
Conclusion: We propose a model in which hepatic DEPTOR accelerates the inhibition of mTORC1 during the transition to fasting to adjust
metabolism to the nutritional status.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The mechanistic target of rapamycin complex 1 (mTORC1) is an
evolutionary conserved serine/threonine kinase that plays important
roles in regulating cell metabolism, growth, and proliferation [1]. In
response to nutrients and growth factors, mTORC1 activates several
processes including protein and lipid synthesis. Studies indicate that
mTORC1 is a key sensor allowing cells and tissues to adapt their
metabolism in response to nutritional cues [1]. mTORC1 regulates
glucose and lipid metabolism by controlling various metabolic pro-
cesses in several organs, including the liver. In this tissue, mTORC1
controls ketogenesis [2], lipogenesis [3e6], glucose metabolism [6],
and mitochondrial dynamics [7] to ensure an appropriate feeding-to-
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activity must be tightly regulated to couple anabolism to the nutritional
state. In response to growth factors (insulin), a cascade of intracellular
events allows phosphatidylinositol 3-kinase (PI3K) to promote the
activity of downstream kinases including protein kinase B (Akt/PKB).
When active, Akt/PKB phosphorylates and inhibits the tuberous scle-
rosis complex (TSC), which acts as a GTPase-activating protein (GAP)
for the small GTPase Ras-homolog enriched in brain (Rheb) [8e10]. In
its GTP-bound state, Rheb stimulates mTORC1 kinase activity [11]. In
parallel, amino acids activate mTORC1 independently of PI3K by pro-
moting the translocation of mTORC1 to the lysosomal surface, where
Rheb resides [12]. The recruitment of mTORC1 on the lysosome, a
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Brief Communicationthe Rag GTPase (RagA, B, C and D) [12], the Ragulator complex [13], v-
ATPase [14], and folliculin [15].
In addition to these upstream regulators, the core proteins composing
mTORC1 also includes modulators of mTORC1 activity, namely DEP
domain-containing mTOR-interacting protein (DEPTOR) and proline-rich
Akt substrate of 40 kDa (PRAS40) [16e18]. The role of these proteins in
regulating mTORC1 action has been well demonstrated in vitro. Over-
expression of both DEPTOR and PRAS40 in cells repress mTORC1
activity, mimicking a state of low nutrients and growth factors [16e18].
Despite these ﬁndings, the roles of these proteins in vivo are still poorly
understood, especially because diverging observations were made
using different approaches and models. For example, peripheral over-
expression of DEPTOR promotes diet-induced obesity [19] whereas its
overexpression in the mediobasal hypothalamus protects mice against
body weight gain [20]. Likewise, liver-speciﬁc overexpression of
PRAS40 or systemic ablation of this protein both improve glucose ho-
meostasis in mice [21,22]. These results indicate that the functions of
these proteins likely differ between cell types and tissues. In this
context, there is a clear need to develop conditional mouse models to
speciﬁcally dissect the role of these proteins in speciﬁc cell populations.
To address these important issues, we developed a novel conditional
knockout mouse for DEPTOR. Here, we report that whole-body deletion
of DEPTOR does not lead to any apparent metabolic disturbances. Both
male and female mice lacking DEPTOR are viable, fertile, normal in
size, and metabolically healthy. Because prenatal DEPTOR deletion
may have led to early developmental compensation inherently masking
the resulting phenotype, we have deleted DEPTOR speciﬁcally in the
liver, a tissue in which DEPTOR protein is expressed and regulated in
response to mTORC1 activation. Using two different approaches, we
show that postnatal liver-speciﬁc ablation of DEPTOR reduces circu-
lating glucose upon fasting. This effect was not associated with
changes in hepatic glucose production but was linked to a sustained
reduction in circulating glucose levels during insulin tolerance tests.
Importantly, mice lacking DEPTOR speciﬁcally in liver had reduced
hepatic glycogen content when fasted, together with enhanced
oxidative metabolism in hepatocytes. Sustained mTORC1 activation
upon fasting was responsible for the resulting altered metabolic
transition to fasting, as acute treatment with rapamycin, a speciﬁc
mTORC1 inhibitor, was sufﬁcient to normalize glycemia. Together,
these results indicate that DEPTOR plays an important role in liver
feeding-to-fasting transition by ensuring an optimal inhibition of
mTORC1 when nutrients are low.
2. MATERIAL AND METHODS
2.1. Animal care
Animal care and handling were performed in accordance with the
Canadian Guide for the Care and Use of Laboratory Animals and all
experimental procedures received prior approval from the Laval Uni-
versity Animal Care Committee (CPAUL). Male mice were maintained
on a 12-hour light/dark cycle (lights on 0600e1800), while individually
housed in ventilated cages at an ambient temperature of 23  1 C.
2.2. Mouse model generation
For generation of DeptorLoxP/LoxP mice, a BAC clone (identiﬁer: RP24-
167K18, strain: C57BL/6J) containing Deptor locus was obtained
from the RPCI-24 mouse genomic DNA library [23]. Standard PCR and
cloning procedures were used to generate 50 homology arm of 4.2 kb
and a 30 homology arm of 2.4 kb. These arms were cloned into
PGKneoF2L2DTA [24] vector and inserted to surround a fragment of
852 bp containing the exon 2 of Deptor. In the ﬁnal targeting construct,448 MOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elsevierthe neomycin resistance (neo) cassette was ﬂanked LoxP sites and Flp
recognition target (Frt) recombination sites. Deptor exon 2 was ﬂanked
by 50 and 30 LoxP sites. The targeting vector was linearized and
electroporated into embryonic stem cells derived from 129/SvEv mice
[25]. Clones were analyzed for correct integration by Southern blot. The
following primers were used to generate a 519 bp probe to screen for
positive integration (50-CCT AGC ACA TAG GGC GAC TCT CA-30; 50-CAA
GGC CTC AAT TCG ATG CTT-30). This procedure was performed on
genomic DNA that was treated overnight with BamHI (New England
Biolabs, R0136). Positive clones were also validated by PCR. Chimeric
mice were obtained by microinjection of the correctly targeted clones
into BALB/C blastocysts and crossed with C57BL/6J mice to obtain
offspring with germ line transmission. The mice analyzed in this study
were backcrossed to C57BL/6J. Some of the backcrosses involved
mice constitutively expressing the FLP recombinase so as to excise the
neomycin cassette from the targeted allele [26]. All the studies were
performed on littermates with the same genetic background. For the
systemic or liver-speciﬁc invalidation of DEPTOR using Cre mice, mice
were bred to homozygosity for the DeptorLoxP allele and then crossed to
mice expressing the Cre-recombinase transgene from the constitutively
expressed CMV promoter (The Jackson Laboratory, Stock 006054) [27]
or from the liver-speciﬁc albumin promoter (The Jackson Laboratory,
Stock 003574) [28]. In the studies described here, Alb-Li-Deptorwt and
Alb-Li-Deptorko mice were of the following genotype Alb-cre/;
DeptorLoxP/LoxP and Alb-creþ/?; DeptorLoxP/LoxP respectively. In all these
studies, mice were backcrossed to C57BL/6J for at least 6 generations.
For liver-speciﬁc recombination of the DeptorLoxP allele in adult mice,
100 ml of high-titre Ad5 (empty or cre) (3e6)  1010 PFU ml1 was
administered via retro-orbital injection under isoﬂurane anaesthesia.
These studies were performed on DeptorLoxP/LoxP mice backcrossed for
3 generations.
2.3. Genotyping
PCR genotyping of DeptorLoxP/LoxP mice was performed with the
following primers: Deptor forward ¼ 50-TGG CAC TGT CAA GGT GTG
GG-30, Deptor D485 ¼ 50-AAG TCA CCA GCC TGG AAG TG-30, Deptor
reverse ¼ 50-GAT GCG ATT GGG AAG AGA TGA G-30. Using these
primers, an amplicon of 310 bp is produced corresponding to the wild-
type Deptor allele. A fragment of 358 bp is produced corresponding to
the DeptorLoxP allele. An amplicon of 485 bp is detected when the exon
2 is removed upon Cre recombination.
2.4. Glucose, insulin and pyruvate tolerance tests
For the GTT, mice were fasted 16 h (from 1600 to 0800) and were
injected ip with 1 g/kg of D-Glucose (Sigma Aldrich, St Louis, MO). For
the ITT, animals were fasted for 6 h (from 0800 to 1400) and were
injected ip with 0.75 U/kg of insulin (Humulin, Lilly, Canada). For the
PTT, mice were fasted for 16 h (from 1600 to 0800) and were injected
ip with 1 mg/kg sodium pyruvate (Sigma Aldrich). Blood samples were
collected from the tail vein and glucose was measured using a gluc-
ometer (Roche, Accu-Chek Performa).
2.5. Plasma metabolite measurement
Blood was collected using syringes conditioned with EDTA. Plasma
was stored at 80 C for further biochemical analyses. Plasma me-
tabolites were measured using the following commercial kits; insulin
(EMD Millipore, SRI-13K), triglycerides (Thermo Fisher Scientiﬁc,
TR22421), NEFAs (Wako, 999-34691, 995-34791, 991-34891, 993-
35191, 276-76491), and FGF-21 (R&D Systems, MF2100). Circulating
glucose levels were measured from tail blood using an instant gluc-
ometer (Roche, Accu-Chek Performa).GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.6. PET procedure
All in vivo PET experiments were initiated immediately after the insertion
of a cannula in the tail vein for an injection of 11C-acetate PET tracer. All
imaging experiments were performed on the avalanche photodiode-
based small animal PET scanner (LabPET/Triumph, Gamma Medica,
Northridge, CA) of the Sherbrooke Molecular Imaging Centre, having a
7.5 cm axial ﬁeld-of-view. The animals were anaesthetized with iso-
ﬂurane (1.75%, 1.5 L/min) delivered through a nose cone and placed in
the supine position on the scanner bed. A bolus of 11C-acetate (10 MBq,
in 0.2 ml of 0.9% NaCl) was injected via the caudal vein over 30 s after
starting PET data acquisition. A 20-min dynamic data acquisition with
11C-acetate was done to determine liver blood ﬂow and oxidative
metabolism. Low dose mCT scans were obtained using a Gamma
Medica Triumph X-O small-animal CT scanner composed of a 40 W X-
ray tube with a 75 mm focal spot diameter and a 2240  2368 CsI ﬂat
panel X-ray detector. The detector pixel size was 50 mm, and a 2  2
pixels binning scheme was used. Scans were performed at 60 kVp and
230 mA using 512 projections in ﬂy mode to reduce exposure. For 11C-
acetate PET images, a dynamic series of 28 frames (1  30, 12  10,
8  30, 6  90, and 1  300 s) were sorted out, and 3D images were
reconstructed using 15 iterations of a maximum-likelihood expectation-
maximization (MLEM) algorithm incorporating physical description of
the detector response function. Regions of interest (ROIs) were drawn
on short-axis images and conﬁrmed with the mCT scan. Tissue time-
activity curves were generated by those ROI drawn on liver. Input
curves (blood time-activity curve) were extracted by means of a ROI
drawn on the left ventricular cavity blood pool in summed last-frame
images to seek better contrast. The sizes of these almost-circular
ROIs were compared with images of eight cylinders of different di-
ameters from which a recovery factor was extracted and applied to the
ROIs for partial volume correction [29].
2.7. Measurement of glucose uptake by tissues
3H-deoxyglucose ([1,2-3H(N)]-Deoxy-D-glucose) was used to evaluate
glucose uptake in inguinal white adipose tissue (iWAT), epididymal
WAT (eWAT), brown adipose tissue (BAT), heart, gastrocnemius
muscle, and spleen, as previously described [30]. The tracer (Moravek
Biochemicals, Inc. Brea, CA, USA) was dissolved in normal saline
supplemented with 4% bovine serum albumin (BSA). In a ﬁrst set of
experiment, mice received an intraperitoneal bolus of 10 mCi of 3H-
deoxyglucose in a total volume of 150 ml following a 11 h fast (from
2000 to 0700). Four hours following the injection, mice were eutha-
nized with an overdose of anesthetic and tissues were collected,
weighed, and homogenized. In a second set of experiment, mice were
fasted for 6 h (from 0800 to 1400), injected with insulin (0.75 U/kg)
and a bolus of 10 mCi of 3H-deoxyglucose, and euthanized with an
overdose of anesthetic 4 h later. Speciﬁc fractional uptake of 3H-
deoxyglucose was determined using a scintillation counter (liquid
scintillation analyzer Tri-Carb 2900TR, PerkinElmer, Montreal, QC,
Canada), as previously described [31]. Uptake data were expressed as
the percentage of injected dose of [3H] per gram of tissues.
2.8. Hepatic glycogen content extraction and measurement
Glycogen was measured in liver samples as described [32]. Brieﬂy,
glycogen was extracted in 30% KOH saturated with Na2SO4, precipitated
in 95% ethanol, and re-suspended in distilled H2O. After addition of
phenol and H2SO4, absorbance at 490 nm was measured in triplicates.
2.9. Hepatic triglyceride content extraction and measurement
Liver sections (25e50 mg) were homogenized in 900 ml of a 2:1 chlor-
oform:methanol mixture. The homogenate was combined with 300 ml ofMOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.commethanol, vortexed, and centrifuged for 15 min at 3,000 rpm. 825 ml of
supernatant was transferred to a new glass tube, 400 ml of chloroform
and 275 ml of 0.73% NaCl was added, and the resulting mixture was
vortexed for 30 s and centrifuged at 5,000 rpm for 3min. The upper phase
was discarded and 800 ml of a 3/48/47 mixture of chlor-
oform:methanol:NaCl (0.58%) was added to wash the lower phase and
was centrifuged at 5,000 rpm for 3 min. After three washes, the lower
phase was evaporated and resuspended in 1 ml of fresh isopropanol.
Triglyceride levels were determined with a standard assay kit (Thermo
Fisher Scientiﬁc, TR22421) according to the manufacturer’s instructions.
2.10. Cell culture
AML12 cells were purchased fromATCC (CRL-2254) and cultured in a 1:1
mixture of Dulbecco’s modiﬁed Eagle’s medium and Ham’s F12 medium
with 0.005mg/ml insulin, 0.005mg/ml transferrin, 5 ng/ml selenium, and
40 ng/ml dexamethasone, 90%; fetal bovine serum, 10%, as prescribed.
2.11. Virus preparation and cell infection
The vectors used to knock down RFP or DEPTOR are: sh_RFP:
TRCN0000072203; shDeptor_1: TRCN0000110157; shDeptor_2:
TRCN0000110159. The sequence of these hairpins can be retrieved on
the RNAi Consortium (TRC) website http://www.broadinstitute.org/rnai/
public/gene/search. These vectors were co-transfected with the Delta
VPR envelope and CMV VSV-G [33]. Virus-containing supernatants were
collected at 48 h after transfection and ﬁltered using a 0.45m ﬁlter. Cells
were infected for 24 h in the presence of 8 mg/ml polybrene. After
infection, the cells were dispersed into freshmedium. Cells were selected
on the following days with 1 mg/ml puromycin.
2.12. Seahorse experiments
Functional mitochondrial measurements were performed using the
Seahorse XF Cell Mito Stress Test according to manufacturer’s in-
structions. Brieﬂy, AML12 cells were seeded onto an XF24 Cell Culture
Microplate (Agilent Seahorse Bioscience) at 3,000 cells/well and incu-
bated at 37 C overnight in regular media. The following morning,
regular media was replaced for Seahorse XF Base Medium containing
1 mM pyruvate (Gibco, 11360070), 2 mM L-glutamine (Gibco,
25030149) and 25 mM glucose (Sigma, G8270). Cell metabolic rates
were measured using an XF24 Extracellular Flux Analyzer (Agilent
Seahorse Bioscience) following the sequential addition of 1 mM oligo-
mycin (oligo; Sigma 75351; port A), 4 mM carbonyl cyanide 4-(tri-
ﬂuoromethoxy)-phenylhydrazone (FCCP; Sigma, C2920; Port B) and
0.5 mM antimycin A (AA; Sigma, A8674; Port C)þ 0.5 mM rotenone (rot;
Sigma, R8875; Port C). Oxygen consumption rate (OCR) was normalized
to protein concentration using the Protein Assay reagent (Bio-Rad, 500-
0006) and expressed as % from baseline. Non-glycolysis acidiﬁcation
(NGA), glycolysis (G), glycolysis capacity (GC) and glycolytic reserve (GR),
were also evaluated using the Seahorse XF Glycolysis Stress Test ac-
cording tomanufacturer’s instructions. Brieﬂy, AML12 cells were seeded
onto an XF24 Cell Culture Microplate (Agilent Seahorse Bioscience) at
3,000 cells/well and incubated at 37 C overnight in regular media. The
following morning, regular media was replaced for Seahorse XF Base
Medium containing 1 mM L-glutamine (Sigma), and cells were incubated
for one hour at 37 C in a non-CO2 incubator. Extracellular acidiﬁcation
rate (ECAR) was measured following the sequential addition of 10 mM
glucose (Sigma, G8270; port A), 1 mM oligomycin (oligo; Sigma, 75351;
port B), and 50 mM 2-DG (Sigma, D6134; port C).
2.13. Measurement of mitochondrial DNA content
Mitochondrial DNA (mtDNA) content was measured similarly as
described before [34e36]. Brieﬂy, total DNA was isolated using an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 449
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total DNA was used to amplify mtDNA-encoded NADH dehydrogenase I
(ND1) and nuclear DNA-encoded Beta-actin using real-time PCR. The
following primers were used to amplify ND1 (50-ACA AAC ACT TAT TAC
AAC CCA AGA A-30; 50-TTA GGG CGT TTA TTA GAA TAA TGT T-30) and
Beta-Actin (50-AGC GGA CAC TGG CAC AGC CAA CTT-30; 50-AAA TGC
CCA CAC CGC GAC CCT A-30). Relative mtDNA content was calculated
from the ratio of ND1 to genomic Beta-actin.
2.14. Quantitative real-time PCR
Total mRNA was isolated from tissues using the RNeasy Lipid Tissue
Mini Kit (Qiagen, 74104). Total mRNA was isolated from cells using
E.Z.N.A. Total RNA Kit I (Omega Bio-Tek, R6834-02). The RNA con-
centrations were estimated from absorbance at 260 nm. cDNA syn-
thesis was performed using the iScript Advanced cDNA Synthesis Kit
for RT-qPCR (Bio-Rad). mRNA extraction and cDNA synthesis were
performed following the manufacturer’s instructions. cDNA was diluted
in DNase-free water (1:15) before quantiﬁcation by real-time PCR.
mRNA transcript levels were measured in duplicate samples using a
CFX96 or CFX384 touch real-time PCR (Bio-Rad, Mississauga, ON,
Canada). Chemical detection of the PCR products was achieved with
SYBR Green (Bio-Rad, 172-5271). At the end of each run, melt curve
analyses were performed, and representative samples of each experi-
mental group were run on agarose gel to ensure the speciﬁcity of the
ampliﬁcation. Gene expression was corrected for the expression level of
reference genes (Arbp). The following primers were used:Gene Forward primer Reverse primer
Arbp 50-AGAAACTGCTGCCTCACATC-30 50-CATCACTCAGAATTTCAATGG-30
Cs 50-AAGTTGGCAAAGACGTGTCA-30 50-CCGAGACACTCCAAACAGGAC-30
Cytc 50-TGGACCAAATCTCCACGGTCTGTT-30 50-TAGGTCTGCCCTTTCTCCCTTCTT-30
Fgf21 50-CAGCCCTGATGGAATGGATGAGAT-30 50-GAGGCTTTGACACCCAGGATTTGA-30
G6pc 50-GAAGGCCAAGAGATGGTGTGA-30 50-TGCAGCTCTTGCGGTACATG-30
G6pdx 50-GATGTCTTCTGTGGGAGCCA-30 50-CCTATGGTCCCAAAGTCCTTCC-30
Gaa 50-GTCACTGGACAGGGGATGTG-30 50-AGGTAGGGCAGAAGGGCATA-30
Gapdh 50-GGCAAATTCAACGGCACAGT-30 50-CTCGTGGTTCACACCCATCA-30
Glut1 50-CACTGTGGTGTCGCTGTTTG-30 50-AAAGATGGCCACGATGCTCA-30
Glut2 50-ACCTTGGCTTTCACTGTCTTCACT-30 50-ATTCCGCCTACTGCAAAGCT-30
Gpi1 50-TGGAGAAACTCTTGCCACACA-30 50-GAATCATGGGAGGTCACAGCA-30
Gys 50-CGCCGAATTGGCCTTTTCAA-30 50-AAGCTGAGGGATCTGCGATG-30
Hk1 50-ACCTGAATGTAACCGTGGGC-30 50-GCTCTTAGGCGTTCGTAGGG-30
Ldha 50-GCAGTGGAAGGAGGTTCACAA-30 50-GAAGTGCTAGGACACGGGGA-30
Pcx 50-CTGGCTGTAAGCGACCTGAA-30 50-CTTAGCCACCTTGTCCCCTG-30
Pdha 50-ACACAGCATGAGTGACCCTG-30 50-CACCCATCCACCCACCTAAC-30
Pdk1 50-TCCTTAGAGGGCTACGGGAC-30 50-GCTTCCAGGCGGCTTTATTG-30
Pdk2 50-GTACTCCACAGCTCCCACAC-30 50-ATTCAGAGGTGGCAGCATCC-30
Pdk4 50-CAAGGCATCCTGGAGTATAAAG-30 50-CAAAGGCATCTTGGACTACTG-30
Pepck 50-GAGTGGAGACCGCAGGAC-30 50-CAGGTATTTGCCGAAGTTGTAG-30
Pfkfb3 50-ATCCCACGGGAGAGTCCTAC-30 50-GACAGTGTGGAGCGGACATT-30
Pfkm 50-GATGGGTGTGGAAGCAGTGA-30 50-ATTCATCACGGCCACTGTGT-30
Pklr 50-GGCAGATGATGTGGACCGAA-30 50-AAAGGGGAGAGGCGTTTCAG-30
Pkm 50-TCTGTACCGTGGCATCTTCC-30 50-GCCCAGAGTGAGCACTACAA-30
Ppara 50-AGAGCCCCATCTGTCCTCTC-30 50-ACTGGTAGTCTGAAAACCAAA-30
Tkt 50-ATGAGGATTTCCAGGTCGGC-30 50-CACTGCCTCTCCTATGCCAC-302.15. Western blotting
All cells were rinsed twice with ice-cold PBS before lysis. Cells were
lysed with Triton-X 100 containing lysis buffer (50 mM HEPES, pH 7.4,
2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM sodium glycer-
ophosphate, 40 mM NaCl, 50 mM NaF, 2 mM sodium orthovanadate,
1% Triton-X 100, and one tablet of EDTA-free protease inhibitors Roche
per 25 ml). Tissues were homogenized with the same buffer450 MOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elseviersupplemented with 0.1% sodium lauryl sulfate and 1% sodium deox-
ycholate. Cells and tissues were rotated at 4 C for 10 min and then the
soluble fractions of cell lysates were isolated by centrifugation at
maximum speed for 10 min in a microcentrifuge. Protein levels were
then quantiﬁed using Bradford reagents and analyzed by Western
blotting. Samples were loaded on 4e12% Nupage precast gels or 10%
Tris-Glycine gels (Life Technologies). Proteins were transferred to PVDF
membranes blocked in 5% milk diluted in PBS-Tween and incubated
with their primary antibody overnight at 4 C. The following antibodies
were used: Akt (Cell Signaling Technology, 4691, dilution 1:1000),
phospho-AKT S473 (Cell Signaling Technology, 9271, dilution 1:1000),
S6 (Cell Signaling Technology, 2217, dilution 1:2500), phospho-S6
S240/244 (Cell Signaling Technology, 5364, dilution 1:1000), DEP-
TOR (Novus Biologicals, NBP1-49674, lot no. A-2, dilution 1:1000), and
mitochondrial complexes I to V (Abcam, 110413, dilution 1:250). Sec-
ondary antibodies were purchased from Cell Signaling Technology
(7076S and 7074S) and diluted 1:5000. Amersham ECL Western
Blotting Detection Reagent (RPN2106) was used to image the blots.
2.16. Statistical analyses
Data are expressed as mean  SEM. Comparisons between two
experimental conditions were analyzed by Student’s unpaired t test.
Two-way ANOVA was used to compare more than two experimental
conditions. All statistical tests were performed using GraphPad
Prism (version 6.0c), and p < 0.05 was considered statistically
signiﬁcant.3. RESULTS
3.1. Whole-body DEPTOR knockout mice are viable, fertile, normal
in size, and do not display any gross physical or metabolic
abnormalities
In order to investigate the importance of DEPTOR in regulating phys-
iological processes in vivo, we have ﬂoxed Deptor allele by homologousGmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Whole-body DEPTOR null mice are viable, fertile, normal in size, and do not display any gross physical abnormalities. (A) Overview of the strategy developed to
delete Deptor in mice. The exon 2 of Deptor was ﬂoxed with LoxP sites using a targeting vector containing Diphtheria Toxin A and Neomycin resistance cassettes. Positive ES cells
carrying the targeted allele (DeptorNeo) were injected into blastocysts to produce chimeric mice. Following germ line transmission, mice carrying the DeptorNeo allele were crossed
with mice expressing the Flp recombinase to eliminate the Neo cassette, thus creating the DeptorLoxP allele. When crossed with mice expressing the Cre recombinase, the LoxP
sites surrounding the exon 2 of Deptor recombine, which disrupts Deptor coding sequence, by introducing premature STOP codons. (B) Southern blot performed on targeted ES
cells conﬁrming the insertion of the targeting vector in the Deptor locus. (C) Genotyping validation showing the recombination of DeptorLoxP allele in wild-type mice or CMV-cre
mice. (D) Western blot showing the expression of DEPTOR in tissues of Deptor wild-type (wt/wt), heterozygote (D/wt) or knockout (D/D) mice. Akt was used as a loading control. (E)
Mendelian ratios calculated from the crossing of Deptor heterozygote (D/wt) mice. (F) Body weight and (G) tissue weight of whole-body Deptor wild-type and knockout mice. The
data are expressed as the mean  SEM for n ¼ 7e8. (H) Blood metabolites measured in Deptor wild-type or knockout mice. Blood was collected from mice that were fasted
overnight. The data are expressed as the mean  SEM for n ¼ 7e8.recombination. An overview of the strategy and the validation of our
approach are depicted in Figure 1A,B. Brieﬂy, the second exon of
Deptor, which is common to the two Deptor isoforms, was ﬂanked with
LoxP sites to produce DeptorLoxP/LoxP mice. Loss of this exon disrupts
Deptor reading frame and leads to the insertion of premature stop
codons. To determine whether DEPTOR is required for normal mouse
development and growth, DeptorLoxP/LoxP mice were ﬁrst crossed with
mice expressing the Cre recombinase under the control of a human
cytomegalovirus (CMV) minimal promoter (CMV-Cre) (Figure 1C). In this
strain, the Cre gene is expressed early during embryogenesis and
recombination of LoxP sites occurs in all tissues [27]. Because the
recombination is germinal, CMV-cre DeptorLoxP/LoxP mice can transmit
a knockout (KO) allele to their progeny. Here, this allele is deﬁned as
the Deptor D allele. As shown in Figure 1D, this strategy was efﬁcient
to eliminate DEPTOR in all the tissues tested. DEPTOR KO mice are
viable and born at the expected Mendelian ratio (Figure 1E). These
mice are normal and do not show change in body and organ weights
(Figure 1FeG and Supplementary Figure 1AeB). Moreover, we did not
detect signiﬁcant changes in plasma glucose and lipid levels in DEP-
TOR KO mice (Figure 1H and Supplementary Figure 1C). Together,
these results indicate that the chronic and systemic deletion of DEP-
TOR has minimal impacts in mice. Whether the absence of phenotypeMOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comin whole-body DEPTOR null mice is due to compensatory mechanisms
secondary to the chronic loss of the protein is possible.
3.2. Liver-speciﬁc DEPTOR knockout mice exhibit lower blood
glucose upon fasting
When active, mTOR phosphorylates DEPTOR, which promotes their
dissociation and the degradation of DEPTOR by the proteasome
(Figure 2A) [16,37e39]. Because DEPTOR is heavily phosphorylated
upon mTOR activation, a clear mobility shift in DEPTOR migration can
be observed by SDS-PAGE [16]. Although, this phenomenon has been
conﬁrmed several times in vitro, it is unknown whether DEPTOR is
similarly regulated in vivo. In response to feeding, insulin and nutrients
rapidly turn on mTORC1 and mTORC2 in the liver [2]. As shown in
Figure 2B, activation of mTOR signaling by feeding induced a clear
mobility shift in DEPTOR protein levels, conﬁrming that the protein is
subject to a similar regulation in cancer cells and in normal tissues.
Because mTOR signaling plays key metabolic roles in the liver, and
because DEPTOR protein is affected in this tissue in response to
nutritional status, we have deleted DEPTOR in hepatocytes by crossing
DeptorLoxP/LoxP mice with mice expressing the Cre recombinase under
the control of Albumin promoter (Alb-cre) (Figure 2C). Since Alb-Cre is
expressed later in development than CMV-Cre [27,40], we reasonedn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 451
EK
F
L M
G H I J
BA C D
Figure 2: Liver-speciﬁc DEPTOR null mice exhibit lower blood glucose levels when fasted. (A) Schematic representation of the regulatory process controlling DEPTOR protein
levels in cells. (B) Western blot analysis showing the impact of fasting and refeeding on DEPTOR in the liver. All mice were fasted for 14 h. One group was sacriﬁced in fasting
condition (Fasted) and the other was given free access to food for 6 h following fasting (Refed). (C) Schematic representation of the strategy used to produce Alb-Li-Deptorwt and
Alb-Li-Deptorko mice. (D) Western blot showing the expression of DEPTOR in tissues of Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Akt was used as a loading control. (E) Glycemia
measured in fasted Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were fasted for 12 h. Results are presented as percentage of control. The data are expressed as the
mean  SEM for n ¼ 5. * indicates p < 0.05 versus Alb-Li-Deptorwt mice. (F) Blood glucose levels measured in fasted Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were fasted
and glucose levels were measured over time. Results are presented as percentage initial blood glucose measure before fasting. The data are expressed as the mean  SEM for
n ¼ 9. * indicates p < 0.05 versus Alb-Li-Deptorwt mice. (G to J) Blood glucose, insulin, triglycerides, and NEFA measured Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were
fasted for 12 h and then refed a normal chow diet for 1, 3, or 6 h. The data are expressed as the mean  SEM for n ¼ 5. * indicates p < 0.05 versus Alb-Li-Deptorwt mice. (K)
Schematic representation of the strategy used to produce Ad5-Li-Deptorwt and Ad5-Li-Deptorko mice. (L) Western blot showing the expression of DEPTOR in tissues of Ad5-Li-
Deptorwt and Ad5-Li-Deptorko mice. Akt was used as a loading control. (M) Glycemia measured in Ad5-Li-Deptorwt and Ad5-Li-Deptorko mice fasted for 10 h. Results are presented
as percentage of control. The data are expressed as the mean  SEM for n ¼ 8e9. * indicates p < 0.05 versus Ad5-Li-Deptorwt mice.
Brief Communicationthat this strategy could limit possible compensatory mechanisms
linked to the chronic loss of DEPTOR. As shown in Figure 2D, this
approach was efﬁcient to speciﬁcally delete DEPTOR in the liver. From
now, we will refer to these mice as the Alb-Li-Deptorko mice. As re-
ported above with the whole-body DEPTOR KO mouse, Alb-Li-Deptorko
mice did not show change in body weight (Supplementary Figure 2A).
Speciﬁcally, liver size was the same between Alb-Li-Deptorwt and Alb-
Li-Deptorko mice (Supplementary Figure 2B). Interestingly, we
observed that Alb-Li-Deptorko mice had reduced fasting blood glucose
levels compared to Alb-Li-Deptorwt mice (Figure 2EeF). This effect
was speciﬁc to glucose and not associated with changes in circulating
insulin, triglycerides or non-esteriﬁed fatty acids (NEFA) between the
genotypes (Supplementary Figure 2CeE). Importantly, the reduction in
fasting glycemia was transient in Alb-Li-Deptorko mice. Hence, over a
long fasting period, the difference between Alb-Li-Deptorwt and Alb-Li-
Deptorko tended to disappear, suggesting that DEPTOR loss alters the
transition, but not the systemic adaptation to fasting (Supplemental
Figure 2F). Supporting a speciﬁc role for DEPTOR in regulating452 MOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elseviermetabolism during fasting, we observed that glucose levels were
normalized when Alb-Li-Deptorko mice were refed (Figure 2G).
Circulating insulin, triglycerides and NEFA were also normal in these
mice upon refeeding (Figure 2HeJ). Food intake was not different
between Alb-Li-Deptorwt and Alb-Li-Deptorko mice (Supplementary
Figure 2G).
To conﬁrm the acute role of DEPTOR in regulating fasting glucose
levels in mice, we have injected adult DeptorLoxP/LoxP mice with type 5
adenoviruses encoding Cre recombinase (Ad5-cre) (Figure 2K). As
shown before, this strategy is efﬁcient to speciﬁcally eliminate ﬂoxed
alleles in the liver of adult mice [2]. A validation of this approach is
shown in Figure 2L. From now, we will refer to these mice as the Ad5-
Li-Deptorko mice. As expected, losing hepatic DEPTOR did not affect
body and liver weight (Supplementary Figure 2HeI). Conﬁrming the
importance of DEPTOR in regulating fasting glycemia, we observed a
progressive reduction in circulating glucose in Ad5-Li-Deptorko mice
(Figure 2M). Altogether, these results suggest a key role for DEPTOR in
regulating fasting glucose levels.GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
3.3. Liver-speciﬁc DEPTOR loss alters systemic glucose
homeostasis
To better deﬁne the impact of hepatic DEPTOR deletion on systemic
glucose homeostasis, we have performed insulin, glucose, and pyru-
vate tolerance tests (ITT, GTT and PTT, respectively) in Alb-Li-Deptorko
and Ad5-Li-Deptorko mice and their wild-type counterparts. First, mice
were subjected to an ITT to measure the impact of hepatic DEPTOR
loss on insulin sensitivity. As shown in Figure 3A,D, both Alb-Li-
Deptorko and Ad5-Li-Deptorko showed a reduction in circulating
glucose compared to control mice following the intraperitoneal injec-
tion of insulin. Mice were next subjected to GTT to assess glucose
tolerance. As shown in Figure 3B,E, we did not observe a consistent
effect of DEPTOR on circulating glucose levels during this test. Finally,
to determine whether the reduction in fasting glucose levels was linked
to a lower capacity for gluconeogenesis, mice were subjected to a PTT.
This test did not reveal any striking differences between Alb-Li-Dep-
torko or Ad5-Li-Deptorko and their respective controls (Figure 3C,F).
Supporting these results, we did not observe changes in the expres-
sion of key gluconeogenic genes in the liver of DEPTOR null mice
(Supplementary Figure 3A). It is interesting that we did not observe a
signiﬁcant reduction in fasting blood glucose levels between control
and liver-speciﬁc DEPTOR null mice prior to initiate GTT and PTT (See
time 0, Figure 3BeC and EeF). This is likely explained by the fact that
mice were subjected to a long fasting prior to these tests. As shown in
Supplemental Figure 2F, the difference in glycemia between control
and liver-speciﬁc DEPTOR null mice disappears upon an extended
fasting period.
To determine whether the reduction in glycemia found in response to
DEPTOR loss was associated with change in glucose uptake by tis-
sues, Alb-Li-Deptorwt and Alb-Li-Deptorko mice were injected with 3H-
deoxyglucose ([1,2-3H(N)]-deoxy-D-glucose), a non-metabolizable
glucose analogue that remains trapped in most tissues following its
uptake. Mice were injected with 3H-deoxyglucose in the fasting state or
following an acute insulin injection. As shown in Figure 3GeH, the loss
of hepatic DEPTOR did not signiﬁcantly affect glucose uptake by tis-
sues in both fasted and insulin-injected mice. The liver is one of the
few tissues that can mobilize 3H-deoxyglucose following its uptake
[30], thus preventing the use of 3H-deoxyglucose to evaluate hepatic
glucose uptake. To circumvent this limitation, we measured the
expression of glucose transporters and several enzymes controlling
glycolysis in the liver of Alb-Li-Deptorwt and Alb-Li-Deptorko mice. As
shown in Figure 3I, we did not observe signiﬁcant difference in the
expression of all these genes. Supporting these results, knocking down
DEPTOR in mouse AML12 hepatocytes did not affect any of the key
parameters of glycolytic ﬂux, including glycolytic capacity (Figure 3Je
L). The results presented above indicate that peripheral glucose uptake
and gluconeogenesis are unlikely to play a major role in the reduction
of blood glucose levels in Alb-Li-Deptorko mice.
3.4. Loss of DEPTOR promotes oxidative metabolism in
hepatocytes
It is well established that hepatic glycogen is an important source of
glucose that is mobilized over the ﬁrst hours of fasting to maintain
blood glucose levels [41]. Because the impact of DEPTOR on fasting
glycemia was transient and occurred only during the ﬁrst phase of food
deprivation, we hypothesized that DEPTOR deletion might have
reduced glycemia by delaying glycogen mobilization by the liver. Ac-
cording to this model, a rise in glycogen content was expected in the
liver of Alb-Li-Deptorko mice. Surprisingly, not only did Alb-Li-Deptorko
mice not exhibit elevated hepatic glycogen content compared to control
mice, but they showed lower hepatic glycogen deposition (Figure 4A).MOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.comSupporting a cell-autonomous role for DEPTOR in regulating glycogen
metabolism in hepatocytes, Alb-Li-Deptorko mice did not show alter-
ation in glycogen deposition in skeletal muscle (Supplementary
Figure 4A). We also observed that hepatic glycogen levels were
rapidly normalized when Alb-Li-Deptorko mice were given access to
food (Supplementary Figure 4B), indicating that DEPTOR loss unlikely
reduced hepatic glycogen accumulation by impairing its synthesis.
Supporting this result, the expression of Glycogen synthase (Gys) was
not affected by DEPTOR loss (Supplementary Figure 4C). In addition to
entering in glycogen synthesis, glucose molecules also serve as key
substrate to support lipogenesis [42]. To test whether DEPTOR loss
altered systemic glucose homeostasis and glycogen deposition by
preferentially promoting lipogenesis, we measured hepatic triglyceride
levels in Alb-Li-Deptorwt and Alb-Li-Deptorko mice. As shown in
Supplemental Figure 4D, DEPTOR deletion did not affect liver triglyc-
eride levels.
As described above, Alb-Li-Deptorko mice were hypoglycemic when
fasted, a phenomenon that occurred concomitantly with a reduction in
hepatic glycogen deposition. Together, these results indicate that
hepatic and circulating glucose levels are reduced upon hepatic
DEPTOR deletion. To determine whether hepatic DEPTOR could affect
circulating glucose levels and hepatic glycogen deposition by pro-
moting glucose oxidation in the liver, we performed positron emission
tomography experiments using 11C-acetate, a metabolic tracer that
allows live measurement of oxidative metabolism by the tricarboxylic
acid (TCA) cycle [9,14,41]. Time-activity curves calculated from 11C-
acetate dynamic scans revealed an elevation in metabolic activity in
the liver of fasted Alb-Li-Deptorko mice (Figure 4B). Interestingly,
knocking down DEPTOR in mouse AML12 hepatocytes increased
mitochondrial maximal respiration (Figure 4CeD). These results indi-
cate that DEPTOR depletion drives liver oxidative metabolism in a
hepatocyte-autonomous fashion. Importantly, this rise in oxidative
metabolism measured in the liver of Alb-Li-Deptorko mice and AML12
cells depleted from DEPTOR was not a consequence of increased in
mitochondrial content or in expression of proteins of the respiratory
chain (Supplementary Figure 4EeH). Nonetheless, we measured el-
evations in Cytc expression in response to DEPTOR depletion
(Figure 4EeF), an effect that may have contributed to promote
oxidative metabolism.
3.5. Rapamycin corrects fasting blood glucose in Alb-Li-Deptorko
mice
To deﬁne whether DEPTOR loss affects circulating glucose levels
during the transition to fasting by acutely modulating mTOR activity,
liver samples were collected from fasted and insulin-injected Alb-Li-
Deptorwt and Alb-Li-Deptorko mice. Consistent with a role for DEPTOR
in inhibiting mTORC1, we observed a rise in the phosphorylation of the
ribosomal protein S6 in the liver of fasted Alb-Li-Deptorko mice
(Figure 4G). DEPTOR loss did not affect the phosphorylation of AKT on
Ser473 and Thr308, which are residues targeted by mTORC2 and
phosphoinositide-dependent kinase-1 (PDK1) respectively (data not
shown). Interestingly, we found that the elevation in S6 phosphoryla-
tion in the liver of Alb-Li-Deptorko mice was detected only in fasted
mice. As shown in Figure 4H, no difference on S6 phosphorylation was
observed in the liver of Alb-Li-Deptorwt and Alb-Li-Deptorko mice
injected with insulin. These results indicate that DEPTOR represses
mTORC1 only in conditions of food deprivation. To determine whether
sustained mTORC1 activation during fasting participates in the
deregulation of glycemia in Alb-Li-Deptorko mice, mice were injected
with a single dose of the mTORC1 inhibitor rapamycin prior to food
deprivation. Although rapamycin did not affect glycemia in controln open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 453
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Figure 3: Liver-speciﬁc DEPTOR loss alters systemic glucose homeostasis. (A) Insulin, (B) glucose, and (C) pyruvate tolerance tests performed in Alb-Li-Deptorwt and Alb-Li-
Deptorko mice. The data are expressed as the mean  SEM for n ¼ 6e9. * indicates p < 0.05 versus Alb-Li-Deptorwt mice. (D) Insulin, (E) glucose, and (F) pyruvate tolerance tests
performed in Ad5-Li-Deptorwt and Ad5-Li-Deptorko mice. The data are expressed as the mean  SEM for n ¼ 7e9. * indicates p < 0.05 versus Ad5-Li-Deptorwt mice. For all the
graphs presented from A to F, the area under the curve (AUC) is presented. 3H-deoxyglucose uptake by tissues in (G) fasted (11 h) or (H) insulin-injected Alb-Li-Deptorwt and Alb-Li-
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Figure 4: DEPTOR loss promotes oxidative metabolism and mTORC1 activity. (A) Hepatic glycogen content in Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were fasted for
12 h and sacriﬁced. The data are expressed as the mean  SEM for n ¼ 5. * indicates p < 0.05 versus Alb-Li-Deptorwt mice. (B) Oxidative activity index measured by PET in the
liver of Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were fasted before the injection of 11C-acetate. The data are expressed as the mean  SEM for n ¼ 4. * indicates p < 0.05
versus Alb-Li-Deptorwt mice. (CeD) Oxygen consumption rate (OCR) in AML12 cells following the sequential addition of oligomycin (oligo; 1 mM), FCCP (4 mM) and antimycin
A þ rotenone (0.5 mM). The data were normalized to protein concentration and are expressed as the mean  SEM for n ¼ 3e4 per condition. (EeF) CytC mRNA expression
measured by quantitative RT-PCR analyses in (E) liver samples isolated from fasting Alb-Li-Deptorwt and Alb-Li-Deptorko mice or (F) AML12 cells in which DEPTOR was knocked
down. The data are expressed as the mean  SEM for n ¼ 7e9 for the liver sample and n ¼ 4e5 for AML12 cells. * indicates p < 0.05 versus control. (GeH) Western blot
showing the impact of DEPTOR loss on the phosphorylation of S6 in (G) fasted mice (12 h) or (H) mice injected with insulin (3.8 IU/Kg, 5 min). Representative samples are shown.
Quantiﬁcations of the blots are shown on the right side of each panel. The data are expressed as the mean  SEM for n ¼ 3e9. * indicates p < 0.05 versus control. (I) Impact of
rapamycin on circulating glucose in Alb-Li-Deptorwt and Alb-Li-Deptorko mice. Mice were injected with rapamycin (2 mg/kg) and then fasted overnight. Glucose levels were
measured the next day. The data are expressed as the mean  SEM for n ¼ 6e7. * indicates p < 0.05 versus Alb-Li-Deptorwt and # indicates p < 0.05 versus Alb-Li-Deptorko
injected with PBS.animals, it normalized fasting blood glucose levels in Alb-Li-Deptorko
mice (Figure 4I). These results indicate that the reduction in circulating
glucose observed in response to hepatic DEPTOR loss is mediated by
mTORC1. We propose a model in which hepatic DEPTOR accelerates
the inhibition of mTORC1 during the transition to fasting to adjust
metabolism to the nutritional status.
4. DISCUSSION
DEPTOR was recently discovered as an mTOR-interacting protein
whose phosphorylation is very sensitive to mTOR activation [16]. The
phosphorylation of DEPTOR promotes its dissociation from mTOR and
favors its degradation by the proteasome [16,37e39]. Because
DEPTOR depletion activates and its overexpression represses mTOR
activity, DEPTOR was characterized as an endogenous inhibitor of both
mTORC1 and mTORC2 [16]. However, recent works performed in mice
have revealed that the impact of DEPTOR on mTOR signaling is
complex and may differ between cell types and tissues [19,20,43,44].
Here, we have developed genetic mouse models to dissect the role of
DEPTOR at the systemic and hepatocyte-speciﬁc levels. We ﬁrst show
that whole-body deletion of DEPTOR does not affect viability, fertility,
growth and metabolism in male and female mice. Although the
absence of phenotype may sound surprising based on the pleiotropicDeptorko mice. The data are expressed as the mean  SEM for n ¼ 5. (I) Quantitative RT-
mice. The data are expressed as the mean  SEM for n ¼ 7e9. (J) Western blot show
Extracellular acidiﬁcation rate (ECAR) in AML12 cells following the sequential addition of glu
the mean  SEM for n ¼ 3e4 per condition. (L) Non-glycolysis acidiﬁcation (NGA), glyco
presented in K.
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to early developmental compensation, as often observed in several
knockout mouse models [45]. For example, it is possible that DEPTOR
loss may have been compensated by the upregulation of other negative
regulators of the pathway, such as PRAS40. Considering this important
issue, we have deleted DEPTOR later in development and speciﬁcally in
the liver, a key metabolic tissue in which DEPTOR protein is expressed
and regulated in response to mTORC1 activation. We found that
postnatal hepatocyte-speciﬁc ablation of DEPTOR reduces circulating
glucose during fasting, an effect that is rapidly lost upon re-feeding.
Importantly, hepatic loss of DEPTOR did not affect the expression of
gluconeogenic genes and the production of glucose during the PTT.
However, glycogen content was reduced and oxidative metabolism
increased in fasted mice lacking DEPTOR. We found that sustained
mTORC1 activation upon fasting was responsible for the altered
metabolic transition to fasting, as acute treatment with the mTORC1
inhibitor rapamycin was sufﬁcient to normalize glycemia. Together,
these results indicate that DEPTOR plays an important role in liver
feeding-to-fasting transition by ensuring the optimal inhibition of
mTORC1 when nutrients are low.
In the liver, mTORC1 regulates several metabolic processes including
ketogenesis [2], lipogenesis [3e6], glucose metabolism [6] and
mitochondrial dynamics [7]. Importantly, liver transition to fasting isPCR analyses of liver samples isolated from fasting Alb-Li-Deptorwt and Alb-Li-Deptorko
ing the expression of DEPTOR in AML12 cells. Akt was used as a loading control. (K)
cose (10 mM), oligomycin (oligo; 1 mM), and 2-DG (100 mM). The data are expressed as
lysis (G), glycolysis capacity (GC), and glycolytic reserve (GR) calculated from the ECAR
n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 455
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disengagement of mTORC1 during the transition to fasting reduces the
overall respiratory capacity of liver mitochondria [7]. The fact that mice
lacking DEPTOR exhibit increased hepatic oxidative metabolism during
fasting supports the idea that DEPTOR is required to fully disengage
mTORC1 when energy is low. In the absence of DEPTOR, mTORC1
remains active, which promotes oxidative metabolism, increases
glycogen depletion and reduces circulating glucose. Supporting this
model, we found that DEPTOR deletion promotes S6 phosphorylation
during fasting and that the mTORC1 inhibitor rapamycin was sufﬁcient
to fully rescue fasting hypoglycemia in mice lacking DEPTOR. These
results are in line with previous observations showing that neonate
knock-in mice that express a constitutively active form of RagA, an
essential mediator of amino acid signals to mTORC1, exhibit a pro-
nounced glycogen depletion and hypoglycemia after birth [46]. Thus,
DEPTOR plays an important role in allowing an appropriate fasting-to-
feeding metabolic transition by affecting mTORC1 activity.
Over the last years, several groups have studied the impact of mTORC1
activation on liver physiology and metabolism. The vast majority of the
studies were based on the conditional deletion of Tsc1, a component of
TSC that negatively regulates mTORC1. Using this model, it was ﬁrst
shown that the chronic activation of mTORC1 increases liver weight
and blocks ketogenesis upon fasting [2], an effect linked to a defect in
the expression of key ketogenic genes, including Ppara [2,6,47].
Several reports next showed that sustained mTORC1 signaling
severely reduces triglyceride deposition in the liver, thus linking he-
patic mTORC1 to lipid metabolism [3e5,48]. It was also reported that
liver-speciﬁc Tsc1 null mice have decreased locomotor activity and
body temperature when fasted [2,4], an effect dependent on an
elevation in ﬁbroblast growth factor-21 (FGF21) expression and
secretion by the liver [4]. In addition to these metabolic studies, one
study showed that chronic activation of hepatic mTORC1 is sufﬁcient to
cause hepatocellular carcinomas in mice [49]. Since TSC1 and DEP-
TOR are both negative regulators of mTORC1, it was expected that
some of the phenotypes reported in liver-speciﬁc Tsc1 null mice would
also be observed in response to DEPTOR deletion. Surprisingly, DEP-
TOR loss did not induce any of these phenotypes. Accordingly, Alb-Li-
Deptorko mice did not have bigger liver and did not show change in
hepatic triglyceride content. We did not observe any impact of DEPTOR
deletion on the expression of Ppara and Fgf21 and in the circulating
levels of FGF21 (Supplementary Figure 5AeB). Moreover, Li-Deptorko
did not develop tumors, even when followed over a period of 12
months (data now shown). Despite being both categorized as inhibitors
of mTORC1, major differences exist between DEPTOR and TSC1 that
likely explain these different results. First, the level of mTORC1 acti-
vation produced from the loss of DEPTOR and TSC1 greatly differs.
Here, we show that DEPTOR deletion increases S6 phosphorylation by
about 25% in the liver of fasted mice. In sharp contrast, losing TSC1
promotes hepatic S6 phosphorylation by several folds in the same
conditions [2,3,6,49]. In addition to generate a more robust impact on
mTORC1 effectors, TSC1 loss is recognized to induce severe insulin
resistance by promoting mTORC1-mediated feedback inhibition of
PI3K [50e55]. The development of insulin resistance secondary to
TSC1 deletion represents a limitation of this model, as it is difﬁcult to
delineate the contribution of mTORC1 versus insulin resistance to the
phenotype studied. In our case, the loss of DEPTOR did not affect PI3K-
Akt/PKB activation. These results likely explain why losing DEPTOR or
TSC1 does not lead to the same physiological outcomes. From a
conceptual standpoint, these results also underline fundamental dif-
ferences between these two proteins. Whereas TSC1 is a master
switch controlling mTORC1 activity, DEPTOR should be seen as a456 MOLECULAR METABOLISM 6 (2017) 447e458  2017 The Authors. Published by Elseviermodulator allowing a better control of mTORC1 when circulating nu-
trients and growth factors are decreasing. Taking this into account, it
would be interesting to compare the metabolic impact of DEPTOR to
another negative modulator of mTORC1, namely PRAS40 [17,18].
Unfortunately, there are currently no studies reporting the impact of
liver-speciﬁc deletion of PRAS40.
We have previously reported that peripheral overexpression of DEPTOR
cell-autonomously promotes adipogenesis [19]. Paradoxically, sys-
temic overexpression of DEPTOR (periphery and brain) was shown to
protect mice against the development of obesity by affecting the
mediobasal hypothalamic regulation of energy balance [20]. In an
attempt to deﬁne precisely which neuronal populations of the medi-
obasal hypothalamus were responsible for the beneﬁcial metabolic
effects of DEPTOR, we have overexpressed DEPTOR speciﬁcally in
proopiomelanocortin (POMC) but found no impact on body weight
regulation [43]. Rather, overexpression of DEPTOR in these neurons
resulted in liver steatosis and insulin resistance following a high-fat
diet [43]. Another group also studied the impact of DEPTOR over-
expression in vivo by overexpressing the protein in skeletal muscle. In
that case, it was reported that DEPTOR overexpression promotes
glycolysis and protects mice from developing insulin resistance [44].
Although these results are complex and involve multifaceted functions
of DEPTOR in different systems, all these studies showed that DEPTOR
overexpression ampliﬁes Akt/PKB signaling by relieving mTORC1-
mediated feedback inhibition of PI3K. Here, we provide evidence
that deleting DEPTOR enhances mTORC1 activity only during fasting,
without impairing PI3K signaling. Our ﬁndings strongly argue that
endogenous DEPTOR plays marginal roles when circulating nutrients
and insulin levels are high, a moment at which mTORC1 is fully active
and DEPTOR targeted to the proteasome [16,37e39]. Forcing DEPTOR
expression in this context reduces but does not fully inhibits mTORC1
activity, which appears to be sufﬁcient to further activate PI3K-Akt/PKB
signaling. Thus, the physiological consequences of manipulating
DEPTOR expression probably depend on the nutritional status. More-
over, because basal mTORC1 activity differs between cell types and
tissues, it is likely that the impact of DEPTOR loss or overexpression
will be different depending on the site targeted.
5. CONCLUSION
In conclusion, we report the development of a conditional mouse model
allowing the study of the physiological functions of DEPTOR in speciﬁc
cell types. Using this model, we found that hepatic DEPTOR regulates
the metabolic transition to fasting by potentiating mTORC1 inhibition
during food restriction. These results highlight the importance of he-
patic DEPTOR in ﬁne-tuning liver metabolism during the feeding-to-
fasting transition.
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